Latest News
Clostridium difficile is now the most common cause of health care associated infections in the USA
A recent publication by Shin, Chaves-Olarte, and Warren has described the global epidemiology of Clostridium difficile infection (CDI) as well as new approaches in management, including fecal microbiota transplantation. The publication cites a 2014 study by Magill SS et al that reported that CDI is the most common cause of health care–associated infections in the United States and accounts for 12% of these infections.
Genetic Signatures has a range of real-time PCR-based products for detection of Clostridium difficile in stool. These products allow rapid detection and are compatible with most real-time PCR instruments. As there is no post-PCR handling required, the potential for environmental contamination is virtually eliminated. Click here for more information.
Abstract:
Clostridium difficile is an anaerobic, Gram-positive, spore-forming, toxin-secreting bacillus that has long been recognized to be the most common etiologic pathogen of antibiotic-associated diarrhea. C. difficile infection (CDI) is now the most common cause of health care–associated infections in the United States and accounts for 12% of these infections (Magill SS et al., N Engl J Med 370:1198–1208, 2014). Among emerging pathogens of public health importance in the United States, CDI has the highest population-based incidence, estimated at 147 per 100,000 (Lessa FC et al., N Engl J Med 372:825–834, 2015). In a report on antimicrobial resistance, C. difficile has been categorized by the Centers for Disease Control and Prevention as one of three “urgent” threats (http://www.cdc.gov/drugresistance/threat-report-2013/). Although C. difficile was first described in the late 1970s, the past decade has seen the emergence of hypertoxigenic strains that have caused increased morbidity and mortality worldwide. Pathogenic strains, host susceptibility, and other regional factors vary and may influence the clinical manifestation and approach to intervention. In this article, we describe the global epidemiology of CDI featuring the different strains in circulation outside of North America and Europe where strain NAP1/027/BI/III had originally gained prominence. The elderly population in health care settings has been disproportionately affected, but emergence of CDI in children and healthy young adults in community settings has, likewise, been reported. New approaches in management, including fecal microbiota transplantation, are discussed.
